
Commentary|Videos|March 21, 2026
Evaluating Practice-Changing Clinical Trials in Newly Diagnosed DLBCL
Author(s)Matthew J. Matasar, MD
Fact checked by: Paige Britt
New DLBCL trials test bispecifics with chemo, BTK add-ons, and MRD-guided preemptive allo CAR-T to cut relapse risk.
The treatment landscape for newly diagnosed diffuse large B-cell lymphoma is on the precipice of a significant shift. With several high-impact randomized clinical trials reaching maturity, clinicians are preparing for a new era of frontline therapy that moves beyond standard R-CHOP.
Matthew J. Matasar, MD, chief of the Division of Blood Disorders at the Rutgers Cancer Institute, provides a comprehensive overview of the ongoing and recently completed studies poised to redefine the standard of care.




























